It may seem an odd analogy, but managing a health issue is a lot like driving a car. We want the fastest, safest and most ...

Enrollment and dosing underway in Phase 3 clinical trial (the“MIRACLE” trial) evaluating Annamycin (naxtarubicin) for the treatment of R/R AML </p ...

A study conducted by researchers from the Agency for Science, Technology and Research (A*STAR), National Cancer Centre Singapore (NCCS) and National University of Singapore (NUS), in collaboration ...

Natera has announced findings from a study evaluating its personalised tumour-informed molecular residual disease (MRD) test, ...

Annamycin has the potential to be safer and more effective than current prescribed anthracyclines to treat serious, hard-to-treat cancers O ...

A recent study has demonstrated that a precision medicine approach improves treatment selection for patients with soft tissue ...

A study conducted by researchers from the Agency for Science, Technology and Research (A*STAR), National Cancer Centre Singapore (NCCS ...

Natera, Inc. , a global leader in cell-free DNA and precision medicine, today announced the results of a study led by Stanford University School of Medicine for the evaluation of Signatera, Natera's ...

1) Poster Su1466: The Tissue Systems Pathology Test Detected ... play an important role in identifying BE patients at higher risk for progression to esophageal cancer, (ii) empower clinicians ...

“The compelling new data being presented at DDW 2025 underpins the important role that TissueCypher can play in identifying patients ... 1) Poster Su1466: The Tissue Systems Pathology Test ...

“The compelling new data being presented at DDW 2025 underpins the important role that TissueCypher can play in identifying patients with BE ... 1) Poster Su1466: The Tissue Systems Pathology Test ...

SELNET elected to sponsor the trial following a comprehensive review of preclinical data, which demonstrated compelling activity of cirtuvivint across multiple soft-tissue sarcoma cell lines and ...